Why don't doctors recommend nattokinase?

If you have wondered why doctors don't recommend nattokinase, the honest answer has nothing to do with a conspiracy.

The largest and longest trial ever run on this enzyme followed 265 adults for a median of 3 years and found no measurable benefit. The study showing dramatic artery improvements was co-authored by employees of the company that made the tablets. That gap is the entire answer.

Here is what your physician is actually weighing — and where the evidence genuinely does support this enzyme.

Table of Contents

1. The Premise Is Partly Wrong
2. The Best-Designed Trial Came Back Empty
3. The Impressive Study Has an Asterisk
4. No Regulator Has Vouched for What's in the Bottle
5. Doctors Practise Inside Guidelines, and Nattokinase Isn't in Them
6. The Bleeding Risk Is the Caution That's Fully Justified
7. BioAbsorb Nattokinase Enzyme — What a Defensible Label Looks Like
8. Frequently Asked Questions
9. Conclusion
10. Research References

1. The Premise Is Partly Wrong

Start with the assumption buried inside the question, because it does not fully hold. Nattokinase has been eaten in Japan for centuries as natto, and it is studied seriously enough that a US university ran a 3-year randomised trial on it. Integrative and functional medicine practitioners discuss it regularly. The claim that the profession as a whole rejects it is stronger than the facts support.

There is also a quieter reason the conversation feels one-sided: it often never really happens. A 2025 study of internal medicine residents found they scored an average of 42.8% on a test of basic supplement regulation knowledge, with only three-quarters correctly identifying that supplements need no FDA approval before sale. Knowledge gaps were widest on efficacy, safety and adverse event reporting.

So "my doctor didn't recommend it" and "my doctor reviewed the evidence and rejected it" are two very different statements, and most people are describing the first. The rest of this article deals with the doctors who have looked — because their reasons are specific, and worth understanding.

2. The Best-Designed Trial Came Back Empty

This is the fact that does most of the work. The Nattokinase Atherothrombotic Prevention Study, run by the Atherosclerosis Research Unit at the University of Southern California's Keck School of Medicine, randomised 265 adults of median age 65.3 to either 2,000 fibrinolytic units of nattokinase daily or a matching placebo, then followed them for a median of 3 years.

The results were unambiguous. After 3 years, the annualised rate of change in carotid artery intima-media thickness — the imaging measure of early artery disease — did not differ between the two groups. Neither did carotid arterial stiffness. There was no significant effect on blood pressure, and no significant effect on any laboratory measurement taken.

Here is the part supplement marketing tends to skip: this is the design standard medicine runs on. Double-blinded, placebo-controlled, 3 years long, conducted at a major academic centre with no product to sell. When a physician asks what the best evidence shows, this trial is the answer, and the answer is nothing.

One honest caveat belongs here. The trial enrolled healthy adults at low cardiovascular risk — people whose arteries had limited room to improve over 3 years. A null result in that population does not prove nattokinase does nothing in people with existing hyperlipidemia or plaque. It does mean the strongest available evidence gives clinicians no reason to recommend it for prevention.

3. The Impressive Study Has an Asterisk

The counter-evidence people cite is a 2022 study in Frontiers in Cardiovascular Medicine that followed 1,062 participants taking 10,800 FU daily for 12 months. It reported meaningful reductions in carotid artery wall thickness and plaque size, with improvement rates ranging from 66.5% to 95.4%. Those are striking numbers, and they are why the study circulates so widely.

A cardiologist reading it sees four problems immediately:

• It was a retrospective analysis of existing records, not a randomised trial — participants were not assigned to groups by chance
• There was no placebo arm, so there is no way to separate the enzyme's effect from everything else that changed over 12 months
• Several co-authors were employed by Sungen Bioscience, the company that manufactured the nattokinase tablets used throughout
• A corrigendum was published in December 2022, roughly four months after the original paper appeared

There is a dosing gap too. The 10,800 FU used in that study is 5.4 times the 2,000 FU in a standard capsule, and the same paper reported that 3,600 FU produced no lipid-lowering or anti-atherosclerotic effect at all. Anyone taking a 2,000 FU capsule and citing this study is citing a dose they are not taking. Our nattokinase dosage guide covers where the clinically studied range actually sits.

None of this makes the study worthless. It makes it hypothesis-generating rather than practice-changing — a distinction physicians are trained to hold, and one that explains a great deal of the gap between online enthusiasm and clinical caution.

4. No Regulator Has Vouched for What's in the Bottle

This one surprises people. Under the Dietary Supplement Health and Education Act of 1994, the FDA has no authority to approve dietary supplements before they are marketed, and firms generally do not have to give the agency the evidence they rely on for safety, before or after launch.

The burden of proof runs backwards compared with medicines. The NIH Office of Dietary Supplements states plainly that no provision in the law allows the FDA to approve supplements for safety or effectiveness before they reach consumers, and that once a product is on the shelf the agency must prove it unsafe to restrict it. A drug manufacturer has to demonstrate both safety and efficacy first. NCCIH notes that strong evidence behind supplement claims is frequently absent.

Canada handles this differently, which is worth knowing if you are reading from either side of the border. Health Canada requires a Natural Product Number before a natural health product can be sold, issued only after a pre-market review of safety, efficacy and quality.

For a physician, the practical consequence is uncomfortable. Recommending nattokinase means recommending a specific bottle, and enzyme activity is measured in fibrinolytic units that vary between manufacturers. The professional monograph on nattokinase warns that vitamin K2 can remain in a supplement if it is not removed during production — which matters enormously for a warfarin patient, and is not something you can tell by reading the front of the label. If you are evaluating products, the label specifications set out later in this article are a better starting point than brand names.

5. Doctors Practise Inside Guidelines, and Nattokinase Isn't in Them

Clinical practice is guideline-driven, and the guidelines on supplements for cardiovascular prevention are consistently unenthusiastic. The US Preventive Services Task Force issued a Grade I on vitamin and mineral supplementation for preventing cardiovascular disease and cancer, meaning the evidence is insufficient to weigh benefits against harms, and notes the American Heart Association's position that healthy people should get nutrients from varied food rather than pills.

That prior gets reinforced by trials like SPORT, presented at AHA Scientific Sessions in 2022, which tested six popular heart-health supplements in 199 adults aged 40 to 75 against a low-dose statin and placebo. None of the six lowered LDL cholesterol meaningfully. After enough results like that, clinicians develop a default scepticism that any new supplement has to overcome.

Nattokinase specifically does not appear in major cardiology guidelines. That absence is worth reading correctly: it is not a verdict against the enzyme, it means no guideline committee has formally reviewed it. Recommending something outside guidelines requires a physician to defend the choice individually, which is a meaningfully higher bar than writing a familiar prescription.

Training plays a role as well. A 2025 perspective article in Frontiers in Nutrition reported that most US medical students receive fewer than the recommended 25 hours of nutrition education across their entire degree. A doctor who has never been taught to evaluate supplement evidence will reasonably decline to endorse a supplement.

6. The Bleeding Risk Is the Caution That's Fully Justified

If the previous five reasons are about evidence quality, this one is about patient safety, and it is the reason physicians are right to be careful. Memorial Sloan Kettering's integrative medicine database records internal bleeding that led to death in an elderly woman who took over-the-counter nattokinase for an irregular heartbeat while taking no other blood-thinning medication. That case matters precisely because there was no drug interaction to blame.

The same database documents a patient who self-substituted nattokinase for warfarin after mechanical aortic valve replacement and later required a repeat valve replacement for thrombosis. The professional monograph adds a case report of acute cerebellar hemorrhage in a patient with a prior ischemic stroke who combined nattokinase with aspirin.

These are individual case reports, not population statistics, and 3 cases across a supplement used by many thousands of people is not a high event rate. But they establish a consistent pattern that a clinician has to take seriously:

• Anyone taking warfarin, a DOAC, heparin, aspirin or another antiplatelet drug — the effects add together
• Anyone with a bleeding disorder, active peptic ulcer, or history of hemorrhagic stroke
• Anyone with surgery or dental work scheduled, where a washout period applies
• Anyone pregnant, nursing, or under 18, where no human safety data exists

Our full breakdown of reported side effects, contraindications, and who should stop taking it covers these groups in detail. If you fall into any of them, your doctor's hesitation is not conservatism — it is the correct call.

7. BioAbsorb Nattokinase Enzyme — What a Defensible Label Looks Like

If you decide to proceed, the specifications matter more than the branding. The BioAbsorb Nattokinase Enzyme delivers 100 mg providing 2,000 FU per capsule — within the range studied in the randomised trials pooled by the 2023 meta-analysis, rather than a number chosen for marketing impact.

Three details address concerns raised above. The formulation is free of vitamin K2, which removes the INR complication flagged in the professional monograph for anyone on warfarin. In fairness, the same monograph records a Health Canada concern that removing K2 could itself theoretically raise bleeding risk — one more reason this belongs in a conversation with your prescriber. Delivery uses DRcaps delayed-release capsules, which protect the enzyme through stomach acid without the phthalates used in conventional enteric coatings. And every batch is third-party tested for activity of at least 2,000 FU, plus heavy metals, gluten and microbial contaminants — verification DSHEA does not require of anyone.

It is made in a GMP-certified Canadian facility, is non-GMO, and is free of gluten, nuts, eggs, dairy, fish, shellfish and all animal products. A 180-day supply runs $49.87 — roughly $0.28 per day.

We will not overstate it: 2,000 FU is also the dose that produced a null result in healthy, low-risk adults over 3 years. A good label buys confidence that you are taking the dose the research studied, in a form that survives digestion — not a guarantee of benefit. Any brand telling you otherwise is selling past the evidence.

Frequently Asked Questions

Do any doctors recommend nattokinase?

Yes — integrative and functional medicine physicians discuss it regularly, and it is a mainstream functional food in Japan. What no doctor can currently do is point to a guideline recommendation, because no guideline committee has formally evaluated nattokinase at all. The closest analogue is the USPSTF's Grade I rating, and that covers vitamin and mineral supplementation — a different category of product entirely.

Is nattokinase banned or unapproved?

Neither. It is legally sold in the US as a dietary supplement and in Canada under a Natural Product Number, but "not approved" and "unapproved" describe different things — the FDA has no mechanism to approve any supplement, so the absence of approval is a feature of the 1994 law rather than a judgement on this enzyme.

Why is the 1,062-person plaque study cited so often if it has problems?

Because its headline numbers are the most impressive in the field — improvement rates of 66.5% to 95.4% over 12 months are hard to ignore. The design limitations sit in the methods section, where most readers never reach, and the 10,800 FU dose used is 5.4 times what a standard capsule provides.

Can I take nattokinase if I am already on a blood thinner?

Not without your prescribing physician's explicit agreement. Nattokinase has additive fibrinolytic activity with anticoagulant and antiplatelet drugs, and Memorial Sloan Kettering advises against the combination. Our guide to nattokinase as a natural blood thinner covers the interaction in full.

If the biggest trial was null, is there any reason to take it?

The strongest surviving signal is blood pressure: a meta-analysis of 6 randomised trials in 546 participants found a systolic reduction of 3.45 mmHg. That is real but modest, and considerably less than prescription antihypertensives deliver, so it is best understood as supportive rather than primary treatment.

Conclusion

Doctors are cautious about nattokinase because the best-designed trial found nothing over 3 years, the most impressive study carried manufacturer co-authors, and no regulator reviews what goes into the capsule. If you decide the modest blood pressure evidence is worth acting on, take that decision with your physician — and start with a 2,000 FU, K2-free, third-party tested capsule so that at least the contents are not in question.

Research References

1. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical Hemorheology and Microcirculation, Vol. 78, Issue 4 (2021), pp. 339–353. Randomised 265 adults to 2,000 FU nattokinase or placebo for a median of 3 years and found no significant difference in carotid intima-media thickness, carotid arterial stiffness, blood pressure, or any laboratory measure — the primary evidence behind clinical caution.
2. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine, Vol. 9 (2022). Reported carotid plaque and wall thickness improvements of 66.5–95.4% at 10,800 FU daily over 12 months, with no effect at 3,600 FU; retrospective design, absence of a placebo arm, and manufacturer-affiliated authorship are the limitations discussed in this article. A corrigendum was published 5 December 2022 (Vol. 9, 1076420).
3. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, Vol. 24, Issue 8 (2023). Pooled 6 randomised controlled trials and 546 participants, finding a systolic blood pressure reduction of 3.45 mmHg and inconsistent lipid effects at lower doses.
4. Knowledge Gaps and Educational Interventions in Dietary Supplement Regulations Among Resident Physicians. Cureus, Vol. 17, Issue 2 (2025). Found an average knowledge test score of 42.8% among internal medicine residents, with 75% correctly identifying that supplements require no FDA approval before marketing, and knowledge gaps concentrated in efficacy, safety, adverse event reporting and third-party certification.
5. The undernourished curriculum: What happened to nutritional education in the medical curriculum? Frontiers in Nutrition, Vol. 12 (2025). Perspective article reporting that most US medical students receive fewer than the recommended 25 hours of nutrition education, and examining the resulting gap in clinical nutrition competence.
6. Nattokinase — About Herbs, Botanicals & Other Products. Memorial Sloan Kettering Cancer Center, Integrative Medicine Service (2022). Documents fatal internal bleeding in a patient taking nattokinase without concurrent anticoagulants, valve thrombosis following self-substitution for warfarin, and additive bleeding risk with blood-thinning drugs.
7. Questions and Answers on Dietary Supplements. US Food and Drug Administration. Confirms that under DSHEA the FDA cannot approve dietary supplements before marketing and that firms generally need not submit substantiating safety evidence.
8. Dietary Supplements: Background Information. National Institutes of Health, Office of Dietary Supplements. States that no provision in law permits FDA approval of supplements for safety or effectiveness pre-market, and that the agency must prove a marketed product unsafe to restrict it.
9. Using Dietary Supplements Wisely. National Center for Complementary and Integrative Health. Notes that strong evidence supporting supplement claims is often lacking, in contrast with the pre-market requirements placed on prescription and over-the-counter drugs.
10. Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer. US Preventive Services Task Force (2022). Grade I recommendation — evidence insufficient to assess the balance of benefits and harms; cites the American Heart Association position favouring food sources over supplementation.
11. Six common "heart-health" supplements ineffective at lowering cholesterol compared to statins (SPORT trial). American Heart Association Scientific Sessions (2022). Tested six popular supplements in 199 adults aged 40–75 against low-dose rosuvastatin and placebo, finding no meaningful LDL reduction.
12. Natural Health Product Licensing Bulletin. Health Canada, Natural and Non-prescription Health Products Directorate. Confirms that every natural health product sold in Canada requires a pre-market product licence and Natural Product Number.
13. Nattokinase — Professional Natural Products Monograph. Drugs.com (2026). Notes that vitamin K2 may remain in nattokinase supplements if not removed during production, affecting INR in warfarin patients, and records a case report of acute cerebellar hemorrhage.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.